Advancements in the Management of Ovarian Cancer - Episode 1

Biomarker Testing in Advanced Ovarian Cancer

,

Panelists discuss how biomarker testing for advanced ovarian cancer, including when and which biomarkers to test (such as HRD), plays a crucial role in guiding treatment decisions and personalizing patient care.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Biomarker Testing in Advanced Ovarian Cancer
    EP. 2: Role of Genomic Instability Scores in Treatment Selection
    EP. 3: Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer
    EP. 4: Optimizing PARP Inhibitor Duration
    EP. 5: Overview of PRIMA - Niraparib 1L Maintenance
    EP. 6: Emerging Maintenance Strategies in Advanced/Metastatic Disease: Insights on Combination Therapies and Overcoming PARP Inhibitor Resistance
    EP. 7: Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs

    Video content above is prompted by the following:

    1. How do you typically approach biomarker testing for advanced ovarian cancer?
    • When do you test, and what type of testing do you perform?
    • Which biomarkers do you generally access (eg, HRD, etc), and how do these results help guide your treatment approach?
    x